Key market participants compiled in the report “Global Novel Drug Delivery Systems Market” Research Report by Research Nester include Antares Pharma, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Thermo Fisher Scientific Company, Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, and others.
New York, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Increasing healthcare expenditure and investments in the medical sector, accompanied with the expiration of existing international patents, are boosting the development of new drugs and treatment methods. According to The World Bank, global health expenditure per capita in 2019 was USD 1,121.796, which was a significant increase from USD 874.497 in 2009. The method by which a drug is delivered can have a significant influence on its efficacy. Novel drug delivery system is a new approach to facilitate targeted drug delivery, addressing the limitations of traditional drug delivery systems.
Research Nester has evaluated the current market opportunities in ‘Global Novel Drug Delivery Systems Market’ for the period, i.e., 2022-2031 including the ongoing industry trends and innovations that will help industry players to attain their business targets. Apart from that, the inclusive data on market size, market share and forecast, growth opportunities and challenges for the market players along with worldwide analysis on regions- North America, Latin America, Europe, Asia Pacific and Middle East & Africa has been provided in the report.
The growing prevalence of chronic diseases, including cancer, diabetes mellitus, coronary obstructive pulmonary diseases, ischemic heart diseases, and mental disorders are increasingly boosting the need for research and development activities in the field. According to the data by the World Health Organization (WHO), in 2019, an estimated 1.5 million deaths were directly caused by diabetes, 17.9 million people died from cardiovascular diseases, and 3.23 million deaths were caused by chronic obstructive pulmonary disease (COPD) worldwide. Moreover, 10 million deaths were caused by cancer, in 2020. Further, various technological advancements in the medical sector have improved the scope of specific tissue treatment. Novel drug delivery system can deliver drugs in a more controlled manner. Driven by these factors, the global novel drug delivery systems market is estimated to grow at a CAGR of ~8% over the forecast period.
Get a sample copy of the report@ https://www.researchnester.com/sample-request-3930
Geographically, the global novel drug delivery systems market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Amongst these, the market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period. The growth can be attributed to increasing awareness regarding healthcare amongst people, and improving healthcare facilities in the region. Moreover, the growing healthcare expenditure in the APAC region is estimated to further drive the market growth. For instance, as per The World Bank data, in 2019, the health expenditure per capita in East Asia & Pacific, and South Asia were USD 750.642 and 60.579 respectively.
On the other hand, the market in North America is expected to garner the largest market share during the forecast period. The growth of the market in the region can majorly be attributed to the surge in the prevalence of cancer cases in the region, along with the rising adoption of advanced technology in the field of healthcare. In the year 2020, 1806590 new cases of cancer were diagnosed in the United States, according to the statistics by the National Cancer Institute.
For more information in the analysis of this report, visit: https://www.researchnester.com/reports/novel-drug-delivery-systems-market/3930
The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
The market is segmented by delivery type into oral drug delivery, injectable drug delivery, pulmonary, transdermal drug delivery, implantable drug delivery, and others. Among these, the implantable drug delivery segment is anticipated to hold a substantial share in the global market on the back of increasing adoption of implant treatment for various complex issues, such as cancer, contraception, hormone regulation, diseases related to the eyes and others. Besides this, the surge in the number of implantable drug delivery devices being developed by healthcare organizations, backed by its higher accuracy and success rate, is also expected to add to the growth of the segment in the coming years. For instance, the United States Food and Drug Administration (FDA), recently approved Susvimo, earlier known as Port Delivery System with ranibizumab, that has been developed by F. Hoffmann-La Roche Ltd. The implantable drug delivery system is used for the treatment of people with neovascular or “wet” age-related macular degeneration (nAMD).
Get a Sample PDF of Novel Drug Delivery Systems Market Report@ https://www.researchnester.com/sample-request-3930
The global novel drug delivery systems market is segmented on the basis of end-user.
Global Novel Drug Delivery Systems Market, Segmentation by End User
Some of the prominent players and their company profiling included in the report are Antares Pharma, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Thermo Fisher Scientific Company, Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, and others. The profiling enfolds growth opportunities, challenges, market trends, competitive analysis and positioning, along with the strategies used by them to stay ahead of their competitors.
Do You Have Any Query Or Specific Requirement? Ask to Our Expert: https://www.researchnester.com/ask-the-analyst/rep-id-3930
Explore Our Recent Related Reports:
Hemoperfusion Production Market Segmentation By Adsorption (Charcoal Hemoperfusion and Resin Hemoperfusion); By Application (Hepatic failure, Autoimmune Diseases, Intoxications and Others) – Global Demand Analysis & Opportunity Outlook 2027 Alopecia Treatment Market Segmentation By Disease (Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, Alopecia Universalis and Others); By Drug (Minoxidil, Finasteride and Others); By Gender (Male and Female); By Route of Administration (Oral, Injection and Topical); By Distribution Channel (Online and Offline) – Global Demand Analysis & Opportunity Outlook 2027 Polycystic Ovary Syndrome Treatment Market Segmentation By Drugs (Oral Contraceptives, Insulin-Sensitizing Drugs, Antidepressants, Anti-Androgen Drugs and Others); By Surgery (Laparoscopic Ovarian Drilling and Ovarian Wedge Resection); By Distribution Channel (Online and Offline) – Global Demand Analysis & Opportunity Outlook 2027 Instrument Infection Control Market Segmentation By Product (Cleaning, Disinfection and Sterilization); By End User (Hospitals, Pharmaceuticals & Life Sciences Companies, Academic & Research Institutes, Clinics and Others) - Global Industry Demand Analysis and Opportunity Assessment 2018-2027 Nicotine Cessation Market – Global Industry Demand Analysis and Opportunity Assessment 2018-2027
Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.
Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919
For More Update Follow: - LinkedIn | Twitter | Facebook | Xing
John Mackey is bowing out in the battle between CEOs and a new generation entering the workforce, but as he told "Reason," he’s not leaving silently.
In a call with JPMorgan clients earlier this week, CEO Jamie Dimon offered his thoughts on everything from markets, to geopolitics, to competition, and teambuilding.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
Yahoo Finance health care reporter Anjalee Khemlani looks at which pharmaceutical stocks are being affected by litigation surrounding alleged carcinogenic materials in Zantac derivatives.
Strong crude oil prices have once again brought investors' attention to energy stocks that have long been underperforming. The West Texas Intermediate crude oil price has largely been above $90 per barrel since the beginning of March. Here are two stocks that have delivered solid dividend growth consistently over the years, irrespective of oil prices.
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
The pharma giant hit back at allegations that the use of Zantac, known chemically as ranitidine, increases the risk of cancer.
Alibaba Group Holding Limited (NYSE: BABA) and Tencent Holding Ltd (OTC: TCEHY) submitted the algorithm details of some of their products to China's top internet watchdog, Reuters reports. The submission was a part of China's sweeping crackdown on the sector. The internet platforms faced flak for abusing algorithms to invade user privacy and manipulate their choices. The Cyberspace Administration of China (CAC) published a list of 30 algorithms used in some of the country's most popular apps, in
China's latest military exercises encircling Taiwan in response to U.S. House Speaker Nancy Pelosi’s visit to Taipei last week has clear ramifications for the global economy.
(Bloomberg) -- The globe is in the grips of a climate crisis as temperatures soar and rivers run dry, and yet it’s never been a better time to make money by digging up coal.Most Read from BloombergAuthor Salman Rushdie Stabbed on Lecture Stage in New YorkTrump Calls for Release of Warrant Documents Used in SearchExtreme Heat Uncovers Lost Villages, Ancient Ruins and ShipwrecksThe Fed’s Damage to the Housing Market May Last Years‘Pharma Bro’ Martin Shkreli’s Crypto Token Plunges After Massive Sal
The country is contending with its worst nuclear outages in decades, putting it at greater risk of blackouts this winter than big neighbors experiencing their own energy headaches.
A bill is headed for consideration by the full Senate that would move the age at which you have to start drawing down your retirement plan savings to 75. The House of Representatives passed a similar measure, so sponsors are … Continue reading → The post You're One Step Closer to Being Able to Delay Your RMDs in Retirement appeared first on SmartAsset Blog.
GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation from leading drugmakers.
Demand remains strong for automakers, with supply constraints preventing inventory buildup and supporting strong pricing.
Five Chinese state-owned companies said they intend to delist their American depositary shares from the New York Stock Exchange, as financial regulators in Beijing and Washington remain at loggerheads over U.S. audit requirements. In separate filings to Hong Kong’s stock exchange Friday, PetroChina , China Petroleum & Chemical , Aluminum Corp. of China , China Life Insurance Co , and Sinopec Shanghai Petrochemical Co said they have notified the NYSE that they plan to voluntarily delist their American depositary shares.
Billionaire Mark Cuban is the latest celebrity on the receiving end of investor ire. A group of Voyager Digital customers filed a class-action suit in Florida federal court against Cuban, as well as the basketball team he owns, the Dallas Mavericks, alleging their promotion of the crypto platform resulted in more than 3.5 million investors losing $5 billion collectively. Voyager Digital's CEO, Stephen Ehrlich, was also named as a defendant in the suit.
Sanctions imposed on Russian oil have only had a “limited impact” on production despite a concerted Western effort to isolate Vladimir Putin’s regime, experts have warned.
(Bloomberg) -- Mexico — which imports nearly all of the natural gas it burns — has laid out a somewhat surprising mission: to become one of the world’s top exporters of the fuel, and fast.Most Read from BloombergAuthor Salman Rushdie Attacked on Lecture Stage in New YorkThe Fed’s Damage to the Housing Market May Last YearsStriking Drop in Stress Hormone Predicts Long Covid in StudyTrump Calls for Release of Warrant Documents Used in SearchPutin’s War Sends Russian Economy Back to 2018 in Single
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Berkshire Hathaway's 13F filings don't tell the full story about the company's holdings.